Targeting CD20 in melanoma patients at high risk of disease recurrence

Molecular Therapy

Volumn 20, Issue 5, 2012, Pages 1056-1062

  Pinc, Alice ^a   Somasundaram, Rajasekharan ^b   Wagner, Christine ^a   Hörmann, Marcus ^c   Karanikas, Georgios ^c   Jalili, Ahmad ^a   Bauer, Wolfgang ^a   Brunner, Patrick ^a   Grabmeier Pfistershammer, Katharina ^a   Gschaider, Melanie ^a   Lai, Chiou Yan ^d   Hsu, Mei Yu ^d   Herlyn, Meenhard ^b   Stingl, Georg ^a   Wagner, Stephan N ^a,e  

^a Universitatsklinik fur Dermatologie   (Austria)

^b WISTAR INSTITUTE   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 7 RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RITUXIMAB;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMATOLOGY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; LIVER FUNCTION; MAINTENANCE THERAPY; MALE; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; OVERALL SURVIVAL; PATIENT SAFETY; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PILOT STUDY; RECURRENCE FREE INTERVAL; RESPIRATORY TRACT DISEASE; SEROLOGY; SIDE EFFECT; T LYMPHOCYTE;

EID: 84860531228     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.27     Document Type: Article

References (47)

1. Balch, CM, Gershenwald, JE, Soong, SJ, Thompson, JF, Atkins, MB, Byrd, DR et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
2. Flaherty, KT, Puzanov, I, Kim, KB, Ribas, A, McArthur, GA, Sosman, JA et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
3. Hodi, FS, O'Day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
4. Essner, R, Lee, JH, Wanek, LA, Itakura, H and Morton, DL (2004). Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139: 961-6; discussion 966.
5. Hsueh, EC, Essner, R, Foshag, LJ, Ollila, DW, Gammon, G, O'Day, SJ et al. (2002). Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20: 4549-4554. (Pubitemid 35402957)
6. Leo, F, Cagini, L, Rocmans, P, Cappello, M, Geel, AN, Maggi, G et al. (2000). Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 83: 569-572.
7. Petersen, RP, Hanish, SI, Haney, JC, Miller, CC 3rd, Burfeind, WR Jr, Tyler, DS et al. (2007). Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 133: 104-110.
8. Othus, M, Moon, J and Margolin, K (2011). Melanoma's deadly march to the brain: by what route, and can it be stopped? Cancer 117: 1560-1563.
9. Daud, AI, DeConti, RC, Andrews, S, Urbas, P, Riker, AI, Sondak, VK et al. (2008). Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26: 5896-5903.
10. Spitler, LE, Grossbard, ML, Ernstoff, MS, Silver, G, Jacobs, M, Hayes, FA et al. (2000). Adjuvant therapy of stage III and IV malignant melanoma using granulocytemacrophage colony-stimulating factor. J Clin Oncol 18: 1614-1621. (Pubitemid 30220539)
11. Fecher, LA and Flaherty, KT (2009). Where are we with adjuvant therapy of stage III and IV melanoma in 2009? J Natl Compr Canc Netw 7: 295-304.
12. Quintana, E, Shackleton, M, Sabel, MS, Fullen, DR, Johnson, TM and Morrison, SJ (2008). Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
13. Shackleton, M, Quintana, E, Fearon, ER and Morrison, SJ (2009). Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822-829.
14. Frank, NY, Schatton, T and Frank, MH (2010). The therapeutic promise of the cancer stem cell concept. J Clin Invest 120: 41-50.
15. Clarke, MF and Fuller, M (2006). Stem cells and cancer: two faces of eve. Cell 124: 1111-1115.
16. Boiko, AD, Razorenova, OV, van de Rijn, M, Swetter, SM, Johnson, DL, Ly, DP et al. (2010). Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466: 133-137.
17. Boonyaratanakornkit, JB, Yue, L, Strachan, LR, Scalapino, KJ, LeBoit, PE, Lu, Y et al. (2010). Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol 130: 2799-2808.
18. Fang, D, Nguyen, TK, Leishear, K, Finko, R, Kulp, AN, Hotz, S et al. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337. (Pubitemid 41508000)
19. Held, MA, Curley, DP, Dankort, D, McMahon, M, Muthusamy, V and Bosenberg, MW (2010). Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res 70: 388-397.
20. Kupas, V, Weishaupt, C, Siepmann, D, Kaserer, ML, Eickelmann, M, Metze, D et al. (2011). RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol 131: 944-955.
21. Monzani, E, Facchetti, F, Galmozzi, E, Corsini, E, Benetti, A, Cavazzin, C et al. (2007). Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946. (Pubitemid 46366698)
22. Schatton, T, Murphy, GF, Frank, NY, Yamaura, K, Waaga-Gasser, AM, Gasser, M et al. (2008). Identification of cells initiating human melanomas. Nature 451: 345-349.
23. Wong, CE, Paratore, C, Dours-Zimmermann, MT, Rochat, A, Pietri, T, Suter, U et al. (2006). Neural crest-derived cells with stem cell features can be traced back to multiple lineages in the adult skin. J Cell Biol 175: 1005-1015. (Pubitemid 44969205)
24. Reya, T, Morrison, SJ, Clarke, MF and Weissman, IL (2001). Stem cells, cancer, and cancer stem cells. Nature 414: 105-111. (Pubitemid 33041634)
25. Schmidt, P, Kopecky, C, Hombach, A, Zigrino, P, Mauch, C and Abken, H (2011). Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA 108: 2474-2479.
26. Bajetta, E, Del Vecchio, M, Bernard-Marty, C, Vitali, M, Buzzoni, R, Rixe, O et al. (2002). Metastatic melanoma: chemotherapy. Semin Oncol 29: 427-445. (Pubitemid 35178282)
27. Korn, EL, Liu, PY, Lee, SJ, Chapman, JA, Niedzwiecki, D, Suman, VJ et al. (2008). Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26: 527-534. (Pubitemid 351264344)
28. Hillen, F, Baeten, CI, van de Winkel, A, Creytens, D, van der Schaft, DW, Winnepenninckx, V et al. (2008). Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother 57: 97-106. (Pubitemid 350043652)
29. Hussein, MR, Elsers, DA, Fadel, SA and Omar, AE (2006). Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J Clin Pathol 59: 316-324. (Pubitemid 43344897)
30. Fukunaga-Kalabis, M, Roesch, A and Herlyn, M (2011). From cancer stem cells to tumor maintenance in melanoma. J Invest Dermatol 131: 1600-1604.
31. Roesch, A, Fukunaga-Kalabis, M, Schmidt, EC, Zabierowski, SE, Brafford, PA, Vultur, A et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
32. Gupta, PB, Chaffer, CL and Weinberg, RA (2009). Cancer stem cells: mirage or reality? Nat Med 15: 1010-1012.
33. Gupta, PB, Onder, TT, Jiang, G, Tao, K, Kuperwasser, C, Weinberg, RA et al. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659.
34. Li, X, Lewis, MT, Huang, J, Gutierrez, C, Osborne, CK, Wu, MF et al. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679.
35. Schatton, T and Frank, MH (2009). Antitumor immunity and cancer stem cells. Ann N Y Acad Sci 1176: 154-169.
36. Voog, J and Jones, DL (2010). Stem cells and the niche: a dynamic duo. Cell Stem Cell 6: 103-115.
37. Shah, S, Divekar, AA, Hilchey, SP, Cho, HM, Newman, CL, Shin, SU et al. (2005). Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 117: 574-586. (Pubitemid 41504545)
38. Andreu, P, Johansson, M, Affara, NI, Pucci, F, Tan, T, Junankar, S et al. (2010). FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17: 121-134.
39. Ammirante, M, Luo, JL, Grivennikov, S, Nedospasov, S and Karin, M (2010). B-cellderived lymphotoxin promotes castration-resistant prostate cancer. Nature 464: 302-305.
40. Reuschenbach, M, von Knebel Doeberitz, M and Wentzensen, N (2009). A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58: 1535-1544.
41. Lassila, O, Vainio, O and Matzinger, P (1988). Can B cells turn on virgin T cells? Nature 334: 253-255.
42. Nelson, BH (2010). CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185: 4977-4982.
43. DiLillo, DJ, Yanaba, K and Tedder, TF (2010). B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184: 4006-4016.
44. Abès, R, Gélizé, E, Fridman, WH and Teillaud, JL (2010). Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116: 926-934.
45. Balch, CM, Buzaid, AC, Soong, SJ, Atkins, MB, Cascinelli, N, Coit, DG et al. (2001). Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648. (Pubitemid 32786276)
46. Vidal, L, Gafter-Gvili, A, Salles, G, Dreyling, MH, Ghielmini, M, Hsu Schmitz, SF et al. (2011). Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 103: 1799-1806.
47. Robertson, D, Savage, K, Reis-Filho, JS and Isacke, CM (2008). Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol 9: 13.